Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Key Highlights
- ➤Valion and SKL completed formulation work for oral mucosal BioViscid-Entolimod
- ➤Oral mucosal formulation could provide a needle-free alternative to injectable Entolimod
- ➤Entolimod development targets Acute Radiation Syndrome before or after radiation exposure
- ➤Entolimod program investigates protection involving hematopoietic and gastrointestinal tissues
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“The significance of the changing nuclear landscape(1) extends beyond how electricity is generated - it also raises important questions about how communities and emergency systems prepare for low-probability, high-consequence radiation events.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Nuclear power, AI-driven data centers and the push for resilient critical infrastructure are converging at the same time, and we believe medical preparedness should evolve alongside them.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Our goal is to create the ability to administer Entolimod in a more flexible, scalable and field-deployable approach to radiation protection for both military and civilian populations.”
SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power assumes an increasingly important role in meeting the growing electricity requirements of artificial intelligence, data centers and other digital infrastructure, the expansion of the U.S. nuclear-energy landscape that has been increasingly making headlines across the country is also highlighting the importance of resilient emergency preparedness and medical countermeasures for potential radiological and nuclear events.
Against this backdrop, Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection, believes the evolving U.S. nuclear energy landscape reinforces the importance of advancing medical countermeasures that could be deployed rapidly and at population scale in the event of a radiological or nuclear emergency.
Get started
Create a free account to read the full story.